BioNTech (NASDAQ:BNTX) Shares Up 2.9% – Still a Buy?

Shares of BioNTech SE (NASDAQ:BNTX) were up 2.9% during mid-day trading on Tuesday . The stock traded as high as $117.98 and last traded at $117.49. Approximately 136,530 shares were traded during trading, a decline of 83% from the average daily volume of 806,539 shares. The stock had previously closed at $114.22.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BNTX. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $140.76.

BioNTech Trading Up 3.7 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $28.17 billion, a P/E ratio of -55.95 and a beta of 0.22. The firm has a 50 day moving average of $113.72 and a 200-day moving average of $100.54.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the previous year, the company posted $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities research analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Planning Capital Management Corp raised its position in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. raised its position in BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC raised its position in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares in the last quarter. Daiwa Securities Group Inc. raised its position in BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Caprock Group LLC acquired a new position in BioNTech during the second quarter valued at approximately $206,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.